EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis
Science Advances · 09.05.2025 · 11 (19)
DOI: 10.1126/sciadv.adt0504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 09.05.2025. Verfasst von Sheera R Rosenbaum und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA. Hauptthemen laut MEDLINE: Killer Cells, Natural, NF-kappa B, Chemokine CCL2, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Triple-negative breast cancer cells must evade immune surveillance to metastasize to distant sites, yet this process is not well understood. The Eyes absent (EYA) family of proteins, which are crucial for embryonic development, become dysregulated in cancer, where they have been shown to mediate proliferation, migration, and invasion. Our study reveals an unusual mechanism by which EYA3 reduces the presence of cytotoxic natural killer (NK) cells in the premetastatic niche (PMN) to enhance metastasis, independent of its effects on the primary tumor. We find that EYA3 up-regulates nuclear factor κB signaling to enhance CCL2 expression, which, in contrast to previous findings, suppresses cytotoxic NK cell activation in vitro and their infiltration into the PMN in vivo. These findings uncover an unexpected role for CCL2 in inhibiting NK cell responses at the PMN and suggest that targeting EYA3 could be an effective strategy to reactivate antitumor immune responses to inhibit metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
- Pharmacology and Molecular Medicine Program, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
- Medical Scientist Training Program, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
- Molecular Biology Program, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
- Cancer Biology Program, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
- Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus (AMC), Aurora, CO, USA.
ORCID-Profile: Sheera R Rosenbaum, Connor J Hughes, Kaiah M Fields, Stephen Connor Purdy, Annika L Gustafson, Arthur Wolin, Drake Hampton, Etienne Danis, Christopher Ebmeier, Nicole Spoelstra, Jennifer Richer, Paul Jedlicka, James C Costello, Heide L Ford
Förderung
- NCI NIH HHS
Zitieren
APA
Rosenbaum, S. R., Hughes, C. J., Fields, K. M., Purdy, S. C., Gustafson, A. L., Wolin, A., Hampton, D., Shrivastava, N. M., Turner, N., Danis, E., Ebmeier, C., Spoelstra, N., Richer, J., Jedlicka, P., Costello, J. C., Zhao, R., & Ford, H. L. (2025). EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis. Science Advances, 11(19). https://doi.org/10.1126/sciadv.adt0504
Vancouver
Rosenbaum SR, Hughes CJ, Fields KM, Purdy SC, Gustafson AL, Wolin A, et al. EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis. Science Advances. 2025;11(19). doi:10.1126/sciadv.adt0504
BibTeX
@article{Rosenbaum2025,
author = {Rosenbaum, Sheera R and Hughes, Connor J and Fields, Kaiah M and Purdy, Stephen Connor and Gustafson, Annika L and Wolin, Arthur and Hampton, Drake and Shrivastava, Natasha M and Turner, Nicholas and Danis, Etienne and Ebmeier, Christopher and Spoelstra, Nicole and Richer, Jennifer and Jedlicka, Paul and Costello, James C and Zhao, Rui and Ford, Heide L},
title = {EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {19},
doi = {10.1126/sciadv.adt0504}
}
EUVIMED